Research programme: lysosomal storage disease gene therapies - JCR Pharmaceuticals/Takeda
Latest Information Update: 26 Dec 2023
At a glance
- Originator JCR Pharmaceuticals
- Developer JCR Pharmaceuticals; Takeda
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lysosomal storage diseases
Most Recent Events
- 21 Dec 2023 JCR Pharmaceuticals terminates its R&D agreement with Takeda to develop gene therapies for Lysosomal storage diseases
- 28 Mar 2023 JCR Pharmaceuticals and Takeda agree to co-develop gene therapies for Lysosomal storage diseases
- 28 Mar 2023 Preclinical trials in Lysosomal storage diseases in Japan (Parenteral)